Jounce Therapeutics, Inc.
JNCE · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $57 | $417 | $248 | $289 |
| - Cash | $151 | $96 | $147 | $53 |
| + Debt | $10 | $14 | $17 | $20 |
| Enterprise Value | -$83 | $335 | $117 | $255 |
| Revenue | $82 | $27 | $62 | $148 |
| % Growth | 204.8% | -56.8% | -57.8% | – |
| Gross Profit | $82 | $27 | $62 | $148 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$50 | -$91 | -$45 | $53 |
| % Margin | -61.2% | -338.4% | -72.4% | 35.7% |
| Net Income | -$51 | -$91 | -$44 | $57 |
| % Margin | -62.1% | -337.7% | -70.3% | 38.4% |
| EPS Diluted | -0.99 | -1.82 | -1.24 | 1.66 |
| % Growth | 45.6% | -46.8% | -174.7% | – |
| Operating Cash Flow | -$29 | -$83 | -$28 | -$30 |
| Capital Expenditures | -$1 | -$0 | -$0 | -$1 |
| Free Cash Flow | -$30 | -$84 | -$28 | -$31 |